

# **Ulcerative Colitis - Pipeline Review, H2 2020**

https://marketpublishers.com/r/UFE3B9049CBEN.html Date: October 2020 Pages: 779 Price: US\$ 2,000.00 (Single User License) ID: UFE3B9049CBEN

### **Abstracts**

Ulcerative Colitis - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2020, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by



Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 19, 60, 35, 6, 81 and 21 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 14 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

### SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.



The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

### **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction Ulcerative Colitis - Overview Ulcerative Colitis - Therapeutics Development Ulcerative Colitis - Therapeutics Assessment Ulcerative Colitis - Companies Involved in Therapeutics Development Ulcerative Colitis - Drug Profiles Ulcerative Colitis - Dormant Projects Ulcerative Colitis - Dormant Projects Ulcerative Colitis - Discontinued Products Ulcerative Colitis - Product Development Milestones Appendix



## **List Of Tables**

#### LIST OF TABLES

Number of Products under Development for Ulcerative Colitis, H2 2020 Number of Products under Development by Companies, H2 2020 Number of Products under Development by Universities/Institutes, H2 2020 Products under Development by Companies, H2 2020 Products under Development by Universities/Institutes, H2 2020 Number of Products by Stage and Target, H2 2020 Number of Products by Stage and Mechanism of Action, H2 2020 Number of Products by Stage and Route of Administration, H2 2020 Number of Products by Stage and Molecule Type, H2 2020 Ulcerative Colitis - Pipeline by 9 Meters Biopharma Inc, H2 2020 Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2020 Ulcerative Colitis - Pipeline by Abivax SA, H2 2020 Ulcerative Colitis - Pipeline by Aclaris Therapeutics Inc, H2 2020 Ulcerative Colitis - Pipeline by Affilogic SAS, H2 2020 Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2020 Ulcerative Colitis - Pipeline by Akeso Inc, H2 2020 Ulcerative Colitis - Pipeline by Algernon Pharmaceuticals Inc, H2 2020 Ulcerative Colitis - Pipeline by Alivio Therapeutics Inc, H2 2020 Ulcerative Colitis - Pipeline by Allergan Ltd, H2 2020 Ulcerative Colitis - Pipeline by Alpha Cancer Technologies Inc, H2 2020 Ulcerative Colitis - Dormant Projects, H2 2020 Ulcerative Colitis - Discontinued Products, H2 2020



## **List Of Figures**

#### LIST OF FIGURES

Number of Products under Development for Ulcerative Colitis, H2 2020 Number of Products under Development by Companies, H2 2020 Number of Products by Top 10 Targets, H2 2020 Number of Products by Stage and Top 10 Targets, H2 2020 Number of Products by Top 10 Mechanism of Actions, H2 2020 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020 Number of Products by Top 10 Routes of Administration, H2 2020 Number of Products by Stage and Top 10 Routes of Administration, H2 2020 Number of Products by Stage and Top 10 Routes of Administration, H2 2020 Number of Products by Stage and Top 10 Routes of Administration, H2 2020 Number of Products by Stage and Top 10 Routes of Administration, H2 2020



### I would like to order

Product name: Ulcerative Colitis - Pipeline Review, H2 2020

Product link: https://marketpublishers.com/r/UFE3B9049CBEN.html

Price: US\$ 2,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/UFE3B9049CBEN.html</u>